According to a market research report by Grand View Research, the global spinal implants and devices market was valued at $11.1 billion in 2015 and is projected to grow at a CAGR of 5.8% during the period between 2018 and 2024.The main drivers for this expected growth are the increasing prevalence in the treatment rates of degenerative spine disorders, rapidly growing elderly population, advancements in medical technology, and increasing demand for minimally invasive procedures.The motion preservation technologies segment is anticipated to grow at a faster rate with a CAGR of 6.4%.Major competitive vendors that provide spinal implants and devices include:

  • LDR Holding
  • Orthofix Medical (OFIX)
  • Alphatec Spine
  • Globus Medical (GMED)
  • Zimmer Biomet Holdings (ZBH)
  • NuVasive (NUVA)
  • Stryker Corporation (SYK)
  • Medtronic (MDT)

Acquisition Terms and Rationale

  • In an 8-K filing, RTI disclosed the acquisition price as $100 million in upfront cash, $50 million in RTIX stock and up to another $100 million in cash and up to another $50 million in stock upon the achievement of certain revenue targets between transaction closing and December 31, 2022.The firm also received a commitment from Ares Capital to provide a $100 million senior secured second lien credit facility to finance the transaction.A review of the firm’s most recent 10-Q filing indicates that as of September 30, 2018, RTIX had $10 million in cash and equivalents and $103.1 million in total liabilities.Free cash flow during the three months ended September 30, 2018, was negative ($1.6 million).
  • RTIX is acquiring Paradigm for its differentiated, non-fusion (minimally invasive) spinal implant system.As RTI’s CEO Camille Farhat stated in the deal announcement,
  • RTIX is paying up significantly for Paradigm as part of an ongoing transformation to focus its efforts and capital on differentiated products.It expects Paradigm to be ‘EBITDA accretive within 12 months of closing’ (Q1 2019). Paradigm has $40 million in 2018 TTM revenues, so RTIX is paying up to a maximum of 7.5x TTM revenues.
  • This is a pricey acquisition. By comparison, OrthoFix Medical (OFIX), currently has an EV/Sales multiple of only 2.27x.I agree with RTIX management’s deal presentation that aging U.S. market demographics are favorable to Paradigm’s lead product, but management also hints that it will need to make headway on coverage reimbursement to fully address the available market.

SOURCE:seekingalpha.com

Read the Complete Article:https://seekingalpha.com/article/4220016-rti-surgical-acquire-paradigm-spine-non-fusion-implant-tech